A phase II evaluation of karenitecin (IND 57250) in the third-Line treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Cositecan (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 06 Aug 2008 Actual study completion date is Jul 2008 as reported by ClinicalTrials.gov.
- 06 Aug 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 17 Sep 2005 New trial record.